Leukemia

白血病

• 批准号: 8533073
• 负责人: A. THOMAS LOOK
• 金额: $ 5万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-15 至 2016-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8533073
• 关键词: Basic Science; Boston; Cancer Center; Cancer Center Support Grant; Clinical; Clinical Cancer Center; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Common Neoplasm; Communities; Complex; Cutaneous; Dana-Farber Cancer Institute; Development; Disease; Division of Clinical Sciences; Environment; Fostering; Future; Goals; Human Biology; Leadership; Malignant Neoplasms; Malignant neoplasm of prostate; Molecular; Patients; Pediatric Hospitals; Pharmacology; Phase; Plant Roots; Population; Recording of previous events; Research Support; Structure; Translational Research; base; innovation; leukemia; melanoma; oncology; programs

OVERVIEW The history of the Cancer Center's Clinical Science Division is rooted in the eariiest years of the Cancer Center. It began with the partnership of Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB), which was established in the late 1940s. The fomiation of the DF/HCC consortium has resulted in the development of a new scientific environment that fosters a high degree of inter-institutional collaboration among clinical investigators and with basic and population colleagues. It also has provided invaluable access to a far greater patient base so that promising clinical trials can be conducted in a reasonable timeframe. The result has been an enriched and cohesive scientific community unified through a commitment to translational research and supported by a single clinical tiials structure. Organization The basic organizing unit for stimulating clinical research remains the Clinical Programs. The Clinical Science Division includes ten programs that are disease-focused (e.g.. Prostate Cancer) and one that supports translational pharmacology and early phase trials (TPETT). Cutaneous Oncology and Melanoma is a new Clinical Program in this application. It has had an excellent record of translational discovery, strong multiinstitutional leadership, a favorable record of innovative trials, a renewed SPORE and active membership.

概述 癌症中心的临床科学部门的历史植根于癌症中心最厄运。它始于1940年代后期成立的达纳 - 法伯癌研究所（DFCI）和波士顿儿童医院（CHB）的合作伙伴关系。 DF/HCC财团的烦恼导致了一个新的科学环境的发展，该环境促进了临床研究人员以及基本和人口同事之间高度的机构间合作。它还提供了无价的进入患者基础的宝贵访问，因此可以在合理的时间范围内进行有前途的临床试验。结果是通过对翻译研究的承诺统一的一个丰富而有凝聚力的科学界，并得到了单个临床教学结构的支持。 组织 刺激临床研究的基本组织单位仍然是临床计划。临床科学部门包括十个以疾病为中心的计划（例如前列腺癌），以及支持转化药理学和早期试验（TPETT）的计划。皮肤肿瘤学和黑色素瘤是该应用程序的新临床计划。它拥有转化发现，强大的多机构的出色记录 领导力，创新试验的有利记录，新的孢子和积极的会员资格。